Chronic lymphoproliferative disorders

Current Opinion in Oncology

Volumn 9, Issue 1, 1997, Pages 34-41

  Montserrat, Emilio ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS; BLOOD SAMPLING; CELL GROWTH; CHRONIC DISEASE; HISTOPATHOLOGY; HUMAN; LYMPHOCYTIC INFILTRATION; LYMPHOPROLIFERATIVE DISEASE; MANTLE CELL LYMPHOMA; PRIORITY JOURNAL; REMISSION; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0030998761     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199701000-00006     Document Type: Review

References (60)

1. Catovsky D: Chronic lymphoproliferative disorders. Curr Opin Oncol 1995, 7:3-11.
2. Montserrat E, Rozman C: Chronic lymphocytic leukemia: present status. Ann Oncol 1995, 6:219-235.
3. O'Brien S, del Giglio A, Keating MJ: Advances in the biology and treatment of B-cell chronic lymphocytic leukemia. Blood 1995, 85:307-318.
4. Rozman C, Montserrat E: Chronic lymphocytic leukemia. N Engl J Med 1995, 333:1052-1057.
5. Caligaris-Cappio F: B-chronic lymphocytic leukemia: a malignancy of anti-self B cells. Blood 1996, 87:2615-2620. An excellent and clearly written review putting together different pieces of information regarding the biology of the neoplastic B lymphocyte in CLL.
6. Montserrat E, Bosch F, Rozman C: Chronic lymphocytic leukemia: recent advances in biology, diagnosis, and therapy. Ann Oncol 1997, in press.
7. +), and advanced disease in CLL. Should CLL be considered a syndrome rather than a single disease?
8. Woessner S, Solé F, Pérez-Losada A, Florensa L, Vilá RM: Trisomy 12 is a rare cytogenetic finding in typical chronic lymphocytic leukemia. Leuk Res 1996, 20:369-374.
9. Hernandez JM, Mecucci C, Criel A, Meeus P, Michaux L, van Hoof A, Verhoef G, Louwagie A, Scheiff JM, Michaux JL, Boogaerts M, van den Berghe H: Cytogenetic analysis of B cell chronic lymphoid leukemias classified according to morphologic and immunophenotypic criteria. Leukemia 1995, 9:2140-2146. This report is an important study in which cytogenic abnormalities have been assessed in 609 patients with CLL. The correlation between distinct cytogenetic abnormalities and different chronic lymphoid leukemias is shown.
10. Fegan C, Robinson H, Thompson P, Wittaker JA, White D: Karyotypic evolution in CLL: Identification of a new sub-group of patients with deletions of 11q and advanced or progressive disease. Leukemia 1995, 9:2003-2008.
11. Newcomb EW, Thomas A, Selkirk A, Lee SY, Potmesil M: Frequent homozygous deletions of D13S218 on 13q14 in B-cell chronic lymphocytic leukemia independent of disease stage and retinoblastoma gene inactivation. Cancer Res 1995, 55:2044-2047. This study supports that the DBM gene on 13q14, rather than the Rb gene, is the most likely tumor suppressor gene involved in CLL pathogenesis.
12. Devilder MC, François S, Bosic C, Moreau A, Mellerin MP, Le Paslier D, Bataille R, Moisan JP: Deletion cartography around the D13S25 locus in B cell chronic lymphocytic leukemia and accurate mapping of the involved tumor suppressor gene. Cancer Res 1995, 55:1355-1357.
13. Newcomb EW, el Rouby S, Thomas A: A unique spectrum of p53 mutations in B-cell chronic lymphocytic leukemia distinct from that of other lymphoid malignancies. Mol Carcinog 1995, 14:227-232.
14. Newcomb EW, Rao LS, Giknavorian SS, Lee SY: Alterations of multiple suppressor genes (p53[17p13], p16INKA [9p21], and DBM-[13q14]) in B-cell chronic lymphocytic leukemia. Mol Carcinog 1995, 14:141-146.
15. Delmer A, Ajchebaum-Cymbalista F, Tang R, Ramond S, Faussat AM, Marie JP, Zittoun R: Overexpression of cyclin D2 in chronic B-cell malignancies. Blood 1995, 85:2870-2876.
16. Watanabe T, Ichikawa A, Atto H, Hotta T: Overexpression of the MDM2 oncogene in leukemia and lymphoma. Leuk Lymphoma 1996, 21:391-397.
17. Golay J, Luppi M, Songia S, et al.: Expression of A-myb, but not c-myb and B-myb, is restricted to Burkitt's lymphoma, slg+ B-acute lymphoblastic leukemia, and a subset of chronic lymphocytic leukemias. Blood 1996, 87:1900-1911.
18. Gartenhaus R, Johns MM III, Wang P, Rai K, Sidransky D: Mutator phenotype in a subset of chronic lymphocytic leukemia. Blood 1996, 87:38-41.
19. Panayiotidis P, Jones D, Ganeshaguru K, Foroni L, Hoffbrand AV: Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br J Haematol 1996, 92:97-103. By showing the role of the microenvironment in the homeostasis of CLL cells, this article reminds us the importance of the "milieu" where neoplastic B lymphocytes accumulate and highlights what should be an important field in the study of the biology of CLL.
20. Thomas A, El Rouby S, Reed S, Krajewski S, Silber R, Potmesil M, Newcomb EW: Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutations and bcl-2/bax proteins in drug resistance. Oncogene 1996, 12:1055-1062.
21. McConkey DJ, Chandra J, Wright S, Plunkett W, McDonell TJ, Reed JC, Keating MJ: Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX. J Immunol 1996, 156:2624-2630. These studies explore the complex pathways leading to the inhibition of apoptosis in CLL through the interaction of different genes of the bcl-2 family. A better understanding of why B lymphocytes accumulate in CLL is essential not only to disclose the pathogenesis of the disease but also to find out treatment strategies based on the correction of the abnormalities of CLL homeostasis.
22. Kay NE, Ranheim EA, Peterson LC: Tumor suppressor genes and clonal evolution in B-CLL. Leuk Lymphoma 1995, 18:41-49.
23. Aoki H, Takishita M, Kosaka M, Saito S: Frequent somatic mutations in D and/or JH segments of Ig gene in Waldenström's macroglobulinemia and chronic lymphocytic leukemia (CLL) with Richter's syndrome but not in common CLL Blood 1995, 85:1913-1919.
24. Mainou-Fowler T, Copplestone JA, Prentice AG: Effect of interleukins on the proliferation and survival of B cell chronic lymphocytic leukaemia cells. J Clin Pathol 1995, 48:482-487.
25. Chaouchi N, Wallon C, Goujard C, Tertian G, Rudent A, Caput D, Ferrera P, Minty A, Vazquez A, Delfraissy JF: Interleukin-13 inhibits interleukin-2 induced proliferation and protects chronic lymphocytic leukemia B cells from in vitro apoptosis. Blood 1996, 87:1022-1029.
26. Trentin L, Ceruti A, Zambello R, Sancetta R, Tassinari C, Facco M, Adami F, Rodeghiero F, Agostini C, Semenzato G: Interleukin-15 promotes the growth of leukemic cells of patients with B-cell chronic lymphoproliferative disorders. Blood 1996, 87:3327-3335.
27. Malisan F, Fluckiger AC, Ho S, Guret CH, Banchereau J, Martinez-Valdez H: B-chronic lymphocytic leukemias can undergo isotype switching in vivo and can be induced to differentiate and switch in vitro. Blood 1996, 87:717-724. Provides evidence of a multistep process in the origins of CLL.
28. Dono M, Hashimoto S, Fais F, Trejo V, Allen SL, Lichtman SM, Schulman PH, Vinciguerra VP, Sellars B, Gregersen PK, Ferrarini M, Chiorazi N: Evidence for progenitors of chronic lymphocytic leukemia B cells that undergo intraclonal differentiation and diversification. Blood 1996, 87:1586-1594. This important paper offers compelling evidence of a multistep process in the origin of CLL.
29. Montserrat E, Villamor N, Reverter JC, Brugués RM, Tàssies D, Bosch F, Aguilar JL, Vives Corrons JL, Rozman M, Rozman C: Bone marrow assessment in B-cell chronic lymphocytic leukaemia: aspirate or biopsy? A comparative study in 258 patients. Br J Haematol 1996, 93:111-116.
30. Keating MJ, Lerner S, Kantarjian H, Freireich EJ, O'Brien S: The serum B2-microglobulin (B2M) level is more powerful than stage in predicting response and survival in chronic lymphocytic leukemia (CLL) [abstract]. Blood 1995, 86(suppl 1):606a.
31. Tallman MS, Hakimian D: Purine nucleoside analogs: emerging roles indolent lymphoproliferative disorders. Blood 1995, 86:2463-2474. A comprehensive review of the role of purine analogues in the management of indolent lymphoproliferative disorders.
32. Robertson LE, O'Brien S, Kantarjian S, Koller C, Beran M, Andreeff M, Lerner S, Keating MJ: Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia. Leukemia 1995, 9:943-945.
33. Rai KR, Peterson B, Kolitz J, Elias L, Shephard L, Hines J, Cheson B, Schiffer C, for the CALGB, SWOG, CTG/NCI-C, ECOG, and NCI: Fludarabine induces a high complete remission rate in previously untreated patients with active chronic lymphocytic leukemia (CLL): a randomized intergroup study [abstract]. Blood 1995, 86(suppl 1):607a.
34. The French Cooperative Group on CLL, Johnson S, Smith AG, Löffler H, Ösby E, Juliusson G, Emmerich B, Wyld PJ, Hiddemann W: Multicentre prospective randomised trial of fludarabine versus cyclosphosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukemia. Lancet 1996, 347:1432-1438. Up to now, trials in which fludarabine is being compared to other alternatives in CLL therapy had been only reported in abstract form. This paper is the first regular paper on a trial in which fludarabine has been compared with other therapy (cyclophospamide, doxorubicin, and prednisone [CAP]) in advanced CLL, Response rates are higher with fludarabine than with CAP, and there is a trend for a longer survival in patients with no prior therapy receiving fludarabine; future updates of this trial should be awaited with interest to see whether the higher response rate associated with fludarabine actually translates into a significantly longer survival.
35. Jaksic B, Brugiatelli M, Krc I, Losonczi H, Holowiecki J, Labar B, Schranz V, Planic-Peraica A, Kusec R, Morabito F, Iacopino P, Lutz D: Comparison of high-dose chlorambucil versus Binet's modified CHOP regimen in B-cell chronic lymphocytic leukemia in advanced phase: results of an international multicentric randomized trial [abstract]. Blood 1995, 86(suppl 1):607a.
36. O'Brien S, Kantarjian H, Beran M, Robertson LE, Koller C, Lerner S, Keating MJ: Interferon maintenance therapy for patients with chronic lymphocytic leukemia in remission after fludarabine therapy. Blood 1995, 86:1296-1300.
37. Zanzani PL, Levrero MG, Lauria F, Rondelli D, Zaja F, Russo D, Fanin R, De Rossi G, Maura FR, Bendandi M, et al.: Alpha-interferon as maintenance drug after initial fludarbine therapy for patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma. Haematologica 1994, 79:55-60.
38. Cheson BD: Infectious and immunusuppresive complications of purine analog therapy. J Clin Oncol 1995, 13:2431-2448. A comprehensive review of side-effects related to purine analogues treatment, their mechanisms, risk factors and preventive measures.
39. Myint H, Copplestone A, Orchad J, Craig V, Curtis D, Prentice AG, Harnon MD, Oscier DG, Hamblin TJ: Fludarabine-related autimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Br J Haematol 1995, 91:341-344.
40. Briz M, Cabrera R, Sanjuan I, Fores R, Diez JL, Herrero M, Regidor C, Algora M, Fernandez MN: Diagnosis of transfusion-associated graft-versus-host disease by polymerase chain reaction in fludarabine-treated B-chronic lymphocytic leukaemia. Br J Haematol 1995, 91:409-411.
41. Michallet M, Archimbaud E, Bandini G, Rowlings OA, Deeg HJ, Gahrton G, Montserrat E, Rozman C, Gratwhol A, Gale RP: HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. Ann Intern Med 1996, 124:311-315.
42. Gribben JG, Bartlet-Panditte L, Provan A, Zwicky C, Neuberg D, Maddocks A, Freedmann AS, Soiffer R, Ritz J, Nadler LM: Disease free status and absence of PCR detectable minimal residual disease suggesting eradication of B-CLL following autologous and allogeneic BMT [abstract]. Blood 1995, 86(suppl 1):457a.
43. Michallet M, Archimbaud E, Rowlings PA, Horowitz MM, Apperley J, Gratwohl A, Gale RP, on behalf of the EBMT and IBMTR: Hematopoietic stem cell transplant for chronic lymphocytic leukemia [abstract]. Bone Marrow Transplant 1996, 17 (suppl 1):S3.
44. Mehta J, Powels R, Singhal S, Iveson T, Treleaven J, Catovsky D: Clinical and hematological response of chronic lymphocytic leukemia persisting after allogeneic bone marrow transplantation with the onset of acute graft-versus-host disease. Bone Marrow Transplant 1996, 17:371-375.
45. Cheson BD, Bennet JM, Grever M, Kay N, Keating MJ, O'Brien S, Rai KR:National Cancer Institute-Sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996, 87:4990-4997. The modified guidelines for diagnosis, treatment indications, and response evaluation for CLL proposed by the National Cancer Institute Sponsored/Working Group should contribute to a better management of patients with CLL, particularly in the setting of clinical trials. Because a unique system to evaluate response to therapy is not agreed on, it would be wortwhile to use these guideliness along with those proposed by the International Workshop on CLL where partial remissions are evaluated in terms of change in clinical stage (eg. from C to B or A; from B to A).
46. Bosch F, Campo E, Jares P, Pittaluga S, Muñoz J, Nayach I, Piris MA, Dewolf-Peeters C, Jaffe ES, Rozman C, Montserrat E, Cardesa A: Increased expression of the PRAD1/CCND1 gene in hairy-cell leukaemia. Br J Haematol 1995, 91:1025-30.
47. Schmid M, Porzsolt F: Autocrine and paracrine regulation of neoplastic cell growth in hairy cell leukemia. Leuk Lymphoma 1995, 17:401-410.
48. Mercieca J, Matutes E, Emmet E, Coles H, Catovsky D: 2-Chlorodeoxyadenosine in the treatment of hairy-cell leukaemia: differences in response in patients with and without abdominal lymphadenopathy. Br J Haematol 1996, 93:409-411.
49. Gollard R, Lee TC, Piro LD, Saven A: The optimal management of hairy cell leukemia. Drugs 1995, 49:921-931. An excellent review of HCL treatment with emphasis on the role of purine analogues.
50. Grever M, Kopecky K, Foucar MK, Head D, Bennet JM, Hutchinson RE, Corbett WE, Cassileth PA, Habermann T, Golomb H, Rai K, Eisenhauer E, Appelbaum F, Cheson BD: Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy-cell leukemia: an intergroup study. J Clin Oncol 1995, 13:974-982. This randomized trial clearly demonstrates the superiority of deoxycoformycin [DCF] (Pentostatin) over interferon in terms of response rate and response duration; a longer follow-up is needed to see whether this translates into a longer survival. A number of single arm studies have already provided enough data to forecast that this will be actually the case. Purine analogues (DCF, 2-CDA) are superior to interferon in the management of HCL and should be considered the treatment of choice for this disease.
51. Seymour JF, Estey EH, Keating MJ, Kurzrok R: Response to interferon-alpha in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine. Leukemia 1995, 9:929-932.
52. Juliusson G, Heldal D, Hippe E, Hedenus M, Malm C, Walman K, Stolt CM, Evensen SA, Albertioni F, Tjonnfjord H, Lenkei R, Liliemark J: Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy-cell leukemia. J Clin Oncol 1995, 13:989-995. This study shows that there is no need for continuous infusion of 2-CDA during 7 days to achieve excellent responses in HCL. 2-CDA given subcutaneously is a convenient treatment schedule which facilitates the management of HCL on an ambulatory basis.
53. Juliusson G, Lenkei R, Tjonnford G, Heldal D, Liliemark J: Low-dose chladribine for symptomatic hairy-cell leukaemia. Br J Haematol 1995, 89:637-639.
54. Dierlamm J, Pittaluga S, Wlodarska I, Stul M, Thomas J, Booaerts M, Michaux L, Driessen A, Mecucci C, Cassiman JJ, De Wolf-Peeters Ch, van den Berghe H: Marginal zone B-cell lymphomas of different sites share similar cytogenetic and morphologic features. Blood 1996, 87:299-307. The fact that marginal zone B-cell lymphomas from different sites (ie, mucosa-associated, monocytoid B, and marginal zone lymphoma of the spleen) share not only common morphologic features but the same cytogenetic abnormalities at the level of chromosome 3 would reinforce the appropriateness of the concept of marginal zone B-cell lymphomas; although this notion has been disputed particularly as far as MALT lymphomas are concerned.
55. Troussard X, Valensi F, Duchayne E, Garand R, Felman P, Tulliez M, Henry-Amar M, Bryon PA, Flandrin G: Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients. Br J Haematol 1996, 93:731-736. This large series of patients with SLVL is useful to become familiar with the most important features of the disease, its natural history and treatment possibilities.
56. Weisenburger D, Armitage JO: Mantle cell lymphoma: an entity comes of age. Blood 1996, 87:4483-4494. An excellent and updated review covering biological, clinical, and treatment aspects of this recently rediscovered entity.
57. de Boer CJ, Schuuring E, Dreef E, Peters G, Bartek J, Kluin PhM, van Krieken JHJM: Cyclin D1 protein analysis in the diagnosis of mantle cell lymphoma. Blood 1995, 86:2715-2723.
58. Pittaluga S, Verhoef G, Criel A, Maes A, Nuyts J, Boogaerts M, de Wolf-Peters C: Prognostic significance of bone marrow trephine and peripheral blood smears in 55 patients with mantle cell lymphoma. Leuk Lymph 1996, 21:115-125.
59. Fisher RI, Dahlberg S, Nathwani BN, Banks PM, Miller ThP, Grogan THM: A clinical analysis of two indolent lymphoma entitities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group Study. Blood 1995, 85:1075-1082.
60. Pittaluga S, Bijnens L, Teodorovic I, Hagenbeek A, Meerwaldt JH, Somers R, Thomas J, Noordjik EM, De Wolf-Peeters C: Clinical analysis of 670 cases in two trials of the European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group subtyped according to the revised European-American classification of lymphoid neoplasms: A comparison with Working Formulation. Blood 1996, 87:4358-4367.